CEVOLUTION: Phase III trial of cevostamab + Pd for RRMM

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, investigators presented an overview of the ongoing phase III CEVOLUTION trial evaluating cevostamab in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma. CEVOLUTION is enrolling patients previously treated with an anti-CD38 antibody and lenalidomide, excluding those with prior exposure to pomalidomide and to BCMA-, GPRC5D-, and/or FcRH5-targeted agents. The study features dual primary endpoints of progression‑free survival and MRD‑negative complete response at 9 months, with additional assessment of very good partial response, overall survival, quality of life, and safety. This phase III evaluation builds on findings from the phase Ib CAMMA 1 program, where cevostamab demonstrated meaningful clinical activity and manageable safety as monotherapy and in combination with pomalidomide and dexamethasone. 

This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.